FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316923296> ?p ?o ?g. }

• W2316923296 endingPage "14" @default.
• W2316923296 startingPage "14" @default.
• W2316923296 abstract "CHICAGO – The shingles vaccine does not increase the risk of shingles in people 60 years and older taking biologics for autoimmune or inflammatory conditions, data from more than 7,000 adults show.The findings were presented at the annual meeting of the American College of Rheumatology.They suggest that the current recommendations that biologics users avoid live virus vaccines may be overly cautious, said Dr. Jeffrey R. Curtis of the University of Alabama, Birmingham.The shingles vaccine (Zostavax) is recommended to protect older adults against herpes zoster, Dr. Curtis said, but concerns have been raised that reactivation of the live virus after vaccination for patients taking immunosuppressive medications might increase their risk of a shingles eruption.To determine the risk of shingles in a population taking immunosuppressive medication, Dr. Curtis and his colleagues reviewed Medicare data from 2006 to 2009. They identified 7,781 adults aged 60 years and older who had rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease, and who had received a shingles vaccine while taking medication including biologics, disease-modifying antirheumatic drugs (DMARDs), and oral glucocorticoids. The mean age of the study population was 74 years, most were white women, and none had any evidence of shingles infection at baseline.Overall, the incidence rate for shingles at least 42 days after vaccination was 8 cases/1,000 person-years among vaccinated adults, compared with 12 cases/1,000 person-years in a cohort of unvaccinated adults.In a subset of 636 vaccinated adults who were taking biologics (regardless of concomitant DMARDs or oral glucocorticoids), no cases of shingles were reported within the first 42 days after vaccination, Dr. Curtis emphasized. In fact, vaccination was associated with a decrease in herpes zoster incidence of approximately 30%, he added. By contrast, the incidence rate of shingles in unvaccinated patients taking biologics was 16 per 1,000 person-years. The incidence of infection was not significantly different in vaccinated patients taking biologics than in vaccinated patients taking non-biologic DMARDs, Dr. Curtis added.The study was limited by the lack of information about the disease severity, Dr. Curtis noted. But the findings support the safety and effectiveness of the shingles vaccine for biologics users.There are persistent unmet vaccination needs for patients with diseases that require immunosuppressive therapy, said Dr. Curtis. “A controlled safety trial of the zoster vaccine in biologic users may be indicated to further demonstrate its safety and effectiveness in preventing zoster infection,” he said.The study was supported by the Agency for Healthcare Research and Quality and the National Institutes of Health. Dr. Curtis has received research grants and consulting fees from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Merck, Roche, and UCB. CHICAGO – The shingles vaccine does not increase the risk of shingles in people 60 years and older taking biologics for autoimmune or inflammatory conditions, data from more than 7,000 adults show. The findings were presented at the annual meeting of the American College of Rheumatology. They suggest that the current recommendations that biologics users avoid live virus vaccines may be overly cautious, said Dr. Jeffrey R. Curtis of the University of Alabama, Birmingham. The shingles vaccine (Zostavax) is recommended to protect older adults against herpes zoster, Dr. Curtis said, but concerns have been raised that reactivation of the live virus after vaccination for patients taking immunosuppressive medications might increase their risk of a shingles eruption. To determine the risk of shingles in a population taking immunosuppressive medication, Dr. Curtis and his colleagues reviewed Medicare data from 2006 to 2009. They identified 7,781 adults aged 60 years and older who had rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease, and who had received a shingles vaccine while taking medication including biologics, disease-modifying antirheumatic drugs (DMARDs), and oral glucocorticoids. The mean age of the study population was 74 years, most were white women, and none had any evidence of shingles infection at baseline. Overall, the incidence rate for shingles at least 42 days after vaccination was 8 cases/1,000 person-years among vaccinated adults, compared with 12 cases/1,000 person-years in a cohort of unvaccinated adults. In a subset of 636 vaccinated adults who were taking biologics (regardless of concomitant DMARDs or oral glucocorticoids), no cases of shingles were reported within the first 42 days after vaccination, Dr. Curtis emphasized. In fact, vaccination was associated with a decrease in herpes zoster incidence of approximately 30%, he added. By contrast, the incidence rate of shingles in unvaccinated patients taking biologics was 16 per 1,000 person-years. The incidence of infection was not significantly different in vaccinated patients taking biologics than in vaccinated patients taking non-biologic DMARDs, Dr. Curtis added. The study was limited by the lack of information about the disease severity, Dr. Curtis noted. But the findings support the safety and effectiveness of the shingles vaccine for biologics users. There are persistent unmet vaccination needs for patients with diseases that require immunosuppressive therapy, said Dr. Curtis. “A controlled safety trial of the zoster vaccine in biologic users may be indicated to further demonstrate its safety and effectiveness in preventing zoster infection,” he said. The study was supported by the Agency for Healthcare Research and Quality and the National Institutes of Health. Dr. Curtis has received research grants and consulting fees from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Merck, Roche, and UCB." @default.
• W2316923296 created "2016-06-24" @default.
• W2316923296 creator A5015380438 @default.
• W2316923296 date "2012-03-01" @default.
• W2316923296 modified "2023-09-25" @default.
• W2316923296 title "Shingles Vaccine Safe for Elderly on Biologics" @default.
• W2316923296 doi "https://doi.org/10.1016/j.carage.2012.03.010" @default.
• W2316923296 hasPublicationYear "2012" @default.
• W2316923296 type Work @default.
• W2316923296 sameAs 2316923296 @default.
• W2316923296 citedByCount "0" @default.
• W2316923296 crossrefType "journal-article" @default.
• W2316923296 hasAuthorship W2316923296A5015380438 @default.
• W2316923296 hasConcept C126322002 @default.
• W2316923296 hasConcept C16005928 @default.
• W2316923296 hasConcept C187212893 @default.
• W2316923296 hasConcept C203014093 @default.
• W2316923296 hasConcept C22070199 @default.
• W2316923296 hasConcept C2522874641 @default.
• W2316923296 hasConcept C2776260265 @default.
• W2316923296 hasConcept C2777575956 @default.
• W2316923296 hasConcept C2778886723 @default.
• W2316923296 hasConcept C2779001537 @default.
• W2316923296 hasConcept C2780564577 @default.
• W2316923296 hasConcept C2908647359 @default.
• W2316923296 hasConcept C71924100 @default.
• W2316923296 hasConcept C72563966 @default.
• W2316923296 hasConcept C99454951 @default.
• W2316923296 hasConceptScore W2316923296C126322002 @default.
• W2316923296 hasConceptScore W2316923296C16005928 @default.
• W2316923296 hasConceptScore W2316923296C187212893 @default.
• W2316923296 hasConceptScore W2316923296C203014093 @default.
• W2316923296 hasConceptScore W2316923296C22070199 @default.
• W2316923296 hasConceptScore W2316923296C2522874641 @default.
• W2316923296 hasConceptScore W2316923296C2776260265 @default.
• W2316923296 hasConceptScore W2316923296C2777575956 @default.
• W2316923296 hasConceptScore W2316923296C2778886723 @default.
• W2316923296 hasConceptScore W2316923296C2779001537 @default.
• W2316923296 hasConceptScore W2316923296C2780564577 @default.
• W2316923296 hasConceptScore W2316923296C2908647359 @default.
• W2316923296 hasConceptScore W2316923296C71924100 @default.
• W2316923296 hasConceptScore W2316923296C72563966 @default.
• W2316923296 hasConceptScore W2316923296C99454951 @default.
• W2316923296 hasIssue "3" @default.
• W2316923296 hasLocation W23169232961 @default.
• W2316923296 hasOpenAccess W2316923296 @default.
• W2316923296 hasPrimaryLocation W23169232961 @default.
• W2316923296 hasRelatedWork W2165578592 @default.
• W2316923296 hasRelatedWork W2467573732 @default.
• W2316923296 hasRelatedWork W2469713984 @default.
• W2316923296 hasRelatedWork W2601256796 @default.
• W2316923296 hasRelatedWork W2617853256 @default.
• W2316923296 hasRelatedWork W2789567537 @default.
• W2316923296 hasRelatedWork W2981478968 @default.
• W2316923296 hasRelatedWork W3020131431 @default.
• W2316923296 hasRelatedWork W3072690337 @default.
• W2316923296 hasRelatedWork W3099665691 @default.
• W2316923296 hasVolume "13" @default.
• W2316923296 isParatext "false" @default.
• W2316923296 isRetracted "false" @default.
• W2316923296 magId "2316923296" @default.
• W2316923296 workType "article" @default.